FDA Proposes New Rules for Weight-Loss Drug Compounding

The FDA has proposed excluding certain active ingredients used in weight-loss drugs from Novo Nordisk and Eli Lilly on the list of compounds facilities can use for drug production. Unless these drugs appear on the agency's shortage list, compounding would be limited, as no clinical need is identified.

In a significant move, the U.S. Food and Drug Administration has proposed new regulations that could impact the production of weight-loss medications by Novo Nordisk and Eli Lilly.

The FDA aims to exclude the active ingredients of these drugs from being used in compounding unless they are officially listed as in short supply. These components include semaglutide from Novo's Wegovy and Ozempic, along with tirzepatide and liraglutide.

FDA Commissioner Marty Makary emphasized that compounding with bulk drug substances is unlawful without a clear clinical need when approved drugs are available. The proposal marks a crucial step in regulating drug compounding practices.